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ABSTRACT
Objectives: The present study was carried out to evaluate the hydroalcoholic extract of Mucuna pruriens (HAMP) seeds for its acute oral toxicity in 
albino rats.
Methods: Acute oral toxicity of MP seed extract was assessed in albino rats with three different doses of the extract with 175, 550, and 2000 mg/
kg body weight. Body weight, mortality, and clinical signs were recorded on 0 (before administration), 7th, and 14th days. Rats were sacrificed after 
day 14 and observed for any histological changes in the brain, heart, liver, and kidney tissues. Rats were normal up to 1 h and exhibited dullness 
and piloerection after 1 h which continued up to 2–4 h of observation period on day 0 of administration. All animals appeared normal from day 1 to 
throughout the experimental procedure.
Results: No significant changes in the histological structure of the liver, kidney, and heart were noticed except mild congestion and hydropic changes 
only in liver tissue seen for 2000 mg/kg body weight of HAMP seeds. The seed extract of MP is non-toxic to rats and did not show any mortality nor 
the behavioral changes. In addition, it showed an increase in the body weight with the administration up to 2000 mg/kg body weight.
Conclusion: MP seed extract signified as neurosuppressant, and the drug can be used in the treatment of neurological disorders characterized 
by hyperactivity of the neurons. The present data could provide adequate confirmation of the safety of MP for further experimental studies on a 
standardized formulation of the seeds extract.
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INTRODUCTION
Mucuna pruriens (MP) commonly called velvet bean is a tropical 
legume indigenous tree to Africa and tropical Asia. As it is one of the 
best sources of protein content in many African countries, it is used 
as food for humans and also the animal feed [1]. MP seed pods are 
covered with hairs which are rich in 5-Hydroxy tryptamine (5-HT) & if 
they come in touch with skin that causes severe itching [2,3]. Its seeds 
contain many micronutrients including amino acids, zinc, selenium, 
carbohydrates [4], and various plant alkaloids [5]. In addition to these 
ingredients, the seeds’ main ingredient is L-DOPA [6]. In Ayurveda, 
Parkinson’s disease (PD) is referred as Kampavata, which is one among 
eighty Vathaja diseases (Astha Mahagathavatarogas), and there are a 
sufficient number of references explaining in detail for the PD for its 
cause, prognosis, and its treatment using many medicinal formulations 
with main ingredient as the MP seeds [7,8-10]. Numerous research 
works have been proven that MP seeds contain L-DOPA [1,11-13], 
which is a just precursor to the neurotransmitter dopamine during its 
synthesis, which is found in the nigrostriatal pathway of the basal nuclei 
of the midbrain [14].
According to Akhtar et al., the ethanolic extract of seeds of MP possesses 
anti-cataleptic and antiepileptic effect in albino rats, and dopamine 
and serotonin may have a role in such activity [15]. Apart from this, 
it is reported from this plant that it is also having antiurolithiatic [14], 
antidiabetic [15-17], anticancer, and antioxidant properties [18]. 
However, if consumed in large quantities of crude MP seeds as food, 
it is poisonous to mammals [19,20]. This indicates that there is some 
toxicity related to MP.
As per the OECD guidelines before the clinical trial on humans for any 
drug, it should be tested on animals to define its median oral toxicity 
(lethal dose [LD50]) values and its effective/therapeutic dose. The name 
LD50 is an abbreviation for “median LD50 50%.” It is the amount of the 
substance required (usually per body weight) to kill 50% of the test 
population. LD50 is the amount of a drug, given oral all at once, which 
causes the death in >50% (one half) of experimental animals in a 
group [21]. The LD50 is one way to measure the short-term poisoning 
potential (acute toxicity) of a material. Rats and mice are most routinely 
used for the experiment by the toxicologist. It is usually expressed as 
the amount of chemical administered (e.g., mg) per 100 g (for smaller 
animals) or per kilogram (for bigger test subjects) of the body weight 
of the test animal. The LD50 can be found for any route of entry or 
administration, but dermal (applied to the skin) and oral (given by the 
mouth) administration methods are the most common [22-24].
MATERIALS AND METHODS
Plant material
The seeds of MP were collected from the Sri Dharmastala Ayurveda 
Medical College and Research Center, Udupi, Karnataka, India. The plant 
material was stored in ambient conditions for further study.
Preparation of extract
The MP seeds were dried in shade and powdered in our research laboratory 
with the help of pulverizer. The hydroalcoholic extract of MP (HAMP) seeds 
were prepared by soaking 500 g of powdered seeds of MP in 2 liters of 50% 
ethanol and 50% cold distilled water for 24 h, filtered, and concentrated by 
evaporating on water bath till free from water. The extract has been stored 
in airtight container under normal temperature [10].
Experimental animals
This study was performed in a CPCSEA approved laboratory under 
registration number 115/1999/CPCSEA following all ethical practices 
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as laid down in the guidelines for animal care. This study has been 
approved by the Institutional Animal Ethics Committee (IAEC) 
KSHEMA/IAEC/08/2017. The study procedure described in this study 
met the requirements of OECD guidelines for testing of chemicals, 
number 425, “acute oral toxicity-acute toxic class method.”
Female albino rats (9–11 weeks, weighing between 200 and 250 g) 
were used for the experiment. All animals were maintained under 
standard laboratory conditions, with a constant 12 h light/dark cycle 
and controlled temperature (25±2°C) with access to drinking water and 
pellet diet ad libitum [25].
Chemicals
The solvents and chemicals required carboxymethyl cellulose (CMC) as 
a suspending agent and distilled water as a solvent.
Methodology
Female albino rats were selected based on their days of acclimatization. 
The rats were divided into three groups, namely Group A, Group B, and 
Group C, with each group having six rats (n=6). They were kept fasting 
for overnight (but with the free access to water). On the test day 0, the 
rats in each group had received a single dose of the plant extract by 
oral gavage method dosages at 175, 550, and 2000 mg/kg body weight, 
respectively. Approximately after 17 h of fasting but with free access to 
water, the animals were continued with proper diet [5-8].
Calculation for the preparation of the stock solution
•	 Group	A:	175	mg	of	MP	is	mixed	with	50	mg	of	CMC	and	the	mixture	
is dissolved in 10 ml distilled water to get the concentration of 
17.5 mg/ml.
•	 Group	B:	550	mg	of	MP	is	mixed	with	50	mg	of	CMC	and	the	mixture	
is dissolved in 10 ml distilled water to get the concentration of 
55 mg/ml.
•	 Group	C: 2000 mg of MP is mixed with 50 mg of CMC and the mixture 
is dissolved in 10 ml distilled water to get the concentration of 
200 mg/ml.
The animals were observed for the acclimatization before the oral 
gavage of the drug and also daily during the test period for clinical signs 
such as sedative effect, decreased locomotor activity, breathlessness, 
and mortality/viability and were recorded during first 30 min and at 
approximately with the duration of 1, 2, 3, and 4 h after administration 
of test drug on day 0 and daily twice during days 1–14 [24,25]. 
Body weights of all the rats were recorded on test day 0 (before 
administration) and also on test days 7 and 14.
At the end of the 14th day of observation period, the animals were 
deeply anesthetized with ether. All the animals were observed for any 
gross/macroscopic pathological changes, and the brain, liver, heart, and 
kidneys from the representative groups of animals were removed and 
processed for the histological studies as follows [26].
Table 1a: Mortality and clinical signs observed with Mucuna pruriens seed extract (175 mg/kg body weight) in rats over a period of 
14 days
Animal ID No. Test days
0* 1 2 3 4 5 6 7 8 9 10 11 12 13 14
30 min 1 h 2 h 3 h 4 h






D N N N N N N N N N N N N N

































N N N N N N N N N N N N N N






D N N N N N N N N N N N N N
N: Normal, D: Dullness, P: Piloerection
Table 1b: Mortality and clinical signs observed with Mucuna pruriens seed extract (550 mg/Kg body weight) in rats over a period of 
14 days
Animal ID No. Test days
0* 1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Procedure
The animals were deeply anesthetized with ether and fixed on a 
dissection board, and its chest cavity was opened to expose the heart. 
About 15 ml of 0.9% saline was perfused through the left ventricle 
at the rate of 1 ml/min. This was followed by perfusion with 10% 
formalin, about 250 ml/adult rats, at the same rate. The animals were 
decapitated, and 5–6 mm thick coronal section of the brain with the 
cerebral cortex, midbrain, liver, kidneys, and heart were removed and 
kept in 10% formalin for 24 h (post-fixation). Paraffin blocks were 
made given below.
Statistical analysis
Statistical analysis is performed using Student’s t-test and one-way 
ANOVA where ever it is applicable.
RESULTS AND DISCUSSION
Oral administration of HAMP at three different doses for 14 days in albino 
rats did not produce any significant toxicity symptoms in rats, including 
the highest dose tested at 2000 mg/kg body weight. No obvious clinical 
signs were found in any groups at initial 30 min of observation.
Changes in the clinical symptoms such as dullness and piloerection 
were noted after 1 h which continued up to 4 h of observation period 
on 0 day. Rats of all the three doses appeared normal and did not show 
signs of toxicity in their skin, fur, eyes, diarrhea, and behavior from day 
1 and continued to remain normal throughout the experimental period 
(Table 1a-c).
A brief period of dullness on day 0 indicates a possible neurosuppression 
role of the drug extract. We did not find any significant changes in the 
mortality rate in any groups exposed to orally administered HAMP 
Albino rats.
Table 1c: Mortality and clinical signs observed with Mucuna pruriens seed extract (2000 mg/kg body weight) in rats over a period of 
14 days
Animal ID No. Test days
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Table 2a: Physical observations in experimental rats with 
Mucuna pruriens seed extract (175 mg/kg body weight) at 
terminal sacrifice.
Animal ID No. Physical observations in experimental rats
A1 No abnormality detected
A2 No abnormality detected
A3 No abnormality detected
A4 No abnormality detected
A5 No abnormality detected
A6 No abnormality detected
Table 2b: Physical observations in experimental rats with 
Mucuna pruriens seed extract (550 mg/kg body weight) at 
terminal sacrifice
Animal ID No. Physical observations in experimental rats
B1 No abnormality detected
B2 No abnormality detected
B3 No abnormality detected
B4 No abnormality detected
B5 No abnormality detected
B6 No abnormality detected
Table 2c: Physical observations in experimental rats with 
Mucuna pruriens seed extract (2000 mg/kg body weight) at 
terminal sacrifice
Animal ID No. Physical observations in experimental rats
C1 No abnormality detected
C2 No abnormality detected
C3 No abnormality detected
C4 No abnormality detected
C5 No abnormality detected
C6 No abnormality detected
Fig. 1: Histological picture of the liver (magnification, ×40) at the 
dose 2000 mg/kg body weight of HAMP. Arrow mark A - shows 
mild congestion and B - shows hydrophic changes
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No gross abnormalities were observed in any animals until the terminal 
sacrifice period (Table 2a-c).
A significant increase in the body weight was observed in all the 
rats subjected for the study by day 14 as compared to 0 days of the 
experimental animals (Table 3).
Light microscopic examination of sections of various organs such as 
the liver, heart, and kidney of the drug-administered groups showed a 
normal cytoarchitecture and absence of any gross pathological lesions, 
in all the three groups except mild congestion and hydrophilic changes 
found in the liver at the dose 2000 mg/kg body weight of HAMP drug-
administered rats when compared with normal (Fig. 1).
Above results indicate that, after oral administration of the HAMP seed 
extract, rats appeared dull for a brief period (on test day 0), after which 
they became normal throughout the experimental procedure (until 
14 days). Interestingly, no mortality was observed in the rats. This 
temporary dullness indicates a possible role of the neurosuppressive effect 
of the extract. The above experiment has recorded a lethal dose of the 
HAMP which is more than 2000 mg/Kg body weight, and the same values 
can be practiced for the further studies to define its effective dose and the 
therapeutic index, so that it can be safely used as a drug in the treatment 
of neurological disorders characterized by the hyperactivity of neurons. 
Moreover, it was also observed that all the rats had gained body weight by 
the end of the experimental procedure. This establishes that the L-DOPA-
enriched extract of MP is non-cytotoxic to the rats. Based on the results 
obtained, the LD50 of HAMP after single oral administration to female rats, 
observed over a period of 14 days, is >2000 mg/kg body weight. Sardjono 
et al. also showed non-toxic effect of MP seed extracts, but it was carried 
out using ethanol extract, which supports our study [27].
CONCLUSION
MP seed extract was evaluated for its acute oral toxicity  in albino rats. 
It was found that HAMP at high dosage (2000 mg/Kg body weight) was 
non-toxic to the rats and it too aided in bringing in the body weight. In 
addition, a brief period of dullness indicates a possible role of the extract 
in neurosuppression as well. Thus, it can be used safely as a drug in the 
treatment of neurological disorders characterized by the hyperactivity 
of neurons. The results of this study also collectively specify that 
oral administration of HAMP is not connected with any toxicological 
significant effects and the data could provide satisfactory preclinical 
evidence of safety to launch a clinical trial on a standardized formulation 
of the plant extracts. Based on the study, we are able to estimate the LD50 
of the test drug, which can be used safely for further experimental studies 
on the rats, and to calculate its therapeutic dose and also to know it anti-
Parkinsonism effect in rotenone-induced Parkinsonism-diseased rats.
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